This week’s Vaccines Research update highlights regulatory shifts, mixed clinical outcomes, pipeline advancement, and ongoing efforts toward broader infectious disease prevention.
In Today’s Newsletter
Dive deeper
💉 Nuvaxovid shifts to Sanofi in Canada [1] [Canada • 10 Apr 2026]
https://www.biospace.com/press-releases/sanofi-becomes-market-authorization-holder-for-nuvaxovid-in-canada-expanding-covid-19-vaccine-choices-for-canadians
Context: Sanofi became market authorization holder for Nuvaxovid (Novavax-origin, protein-based COVID-19 vaccine) in Canada.
Key point: Sanofi said Nuvaxovid will be available in Canada for the fall 2026–2027 season.
Implication: May influence prescriber choice and payer reviews pending full data.
🫁 TB vaccine readout shows partial progress, no infection block [2] [India • 14 Apr 2026]
https://www.gavi.org/vaccineswork/two-new-tb-vaccine-candidates-show-promise-fail-stop-infection
Context: Gavi summarized a large India trial of VPM1002 and Immuvac in adults and older children.
Key point: The candidates were reported as safe and may reduce risk of active tuberculosis, but they did not prevent infection or fully protect against pulmonary TB.
Implication: Could inform practice and payer discussions, interpretation depends on study design and confounding control.
🦠 GeoVax pitches GEO-MVA as second-source mpox vaccine supply [3] [US • 14 Apr 2026]
https://www.geovax.com/investors/press-releases/geovax-positions-geo-mva-to-address-supply-constraints-in-global-mpox-and-smallpox-vaccine-market
Context: GeoVax described a supply-constrained global orthopoxvirus vaccine market, centered on MVA vaccines.
Key point: GeoVax said GEO-MVA could serve as a second-source MVA vaccine, with Phase 3 initiation planned during 2026.
Implication: Signals pipeline investment and modality expansion.
🎯 Transgene completes randomization for TG4050 Phase 2 [4] [EU • 13 Apr 2026]
https://www.transgene.com/wp-content/uploads/20260413_Transgene_Last-Patient-Randomized_EN.pdf
Context: TG4050 is an individualized neoantigen therapeutic vaccine for adjuvant treatment of HPV-negative head and neck squamous cell carcinoma; 38 patients were randomized in Phase 2.
Key point: Transgene completed patient randomization, with topline 2-year disease-free survival expected by end-Q1 2028.
Implication: May influence prescriber choice and payer reviews pending full data.
👩⚕️ MinervaX adds leadership ahead of pivotal maternal GBS trial [5] [EU • 15 Apr 2026]
https://minervax.com/minervax-strengthens-executive-leadership-team-with-two-strategic-appointments/
Context: MinervaX appointed Jamila Louahed as Chief Development Officer and Hans Henrik Chrois Christensen as Chief Financial Officer.
Key point: The company said the hires support pivotal trial initiation for its maternal Group B Streptococcus vaccine program.
Implication: Signals pipeline investment and modality expansion.
🧬 Stem-targeted flu vaccine reports broad humoral responses [6] [13 Apr 2026]
https://bioengineer.org/new-stem-vaccine-sparks-broad-flu-immunity/
Context: A phase 1/2a study evaluated a group 1 hemagglutinin stem-based influenza vaccine in healthy adults.
Key point: The report said the candidate elicited broad humoral responses and was generally well tolerated, with larger trials still needed.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- Sanofi’s Nuvaxovid transfer adds a named non-mRNA COVID-19 option in Canada, relevant for seasonal respiratory vaccine choice [1].
- The TB readout underscores how hard it remains to prevent infection and transmission, even when candidates show signals on disease progression [2].
- GeoVax is framing mpox/smallpox vaccination as a procurement and resilience market, not only an outbreak-response niche [3].
- TG4050 and MinervaX both moved programs closer to late-stage inflection points, one in oncology, one in maternal immunization [4][5].
- The HA stem result keeps universal-influenza vaccine design in focus, but efficacy in broader populations is still unproven [6].
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Vaccine news from the past two weeks, curated by the LucidQuest team.
FAQ
What changed for Nuvaxovid in Canada?
Sanofi said it is now the market authorization holder for Nuvaxovid in Canada and plans availability for the fall 2026–2027 season [1].
Did VPM1002 or Immuvac prevent TB infection?
No. Gavi’s summary says the candidates did not prevent infection or transmission, though they may reduce risk of active disease in some groups [2].
What is GeoVax claiming for GEO-MVA?
GeoVax is positioning GEO-MVA as a potential second-source MVA vaccine for mpox and smallpox, with Phase 3 planned in 2026 if development proceeds as stated [3].
What is the next key milestone for TG4050?
Transgene said topline data for the primary endpoint, 2-year disease-free survival, are expected by the end of Q1 2028 [4].
Why do the MinervaX hires matter now?
MinervaX linked the appointments directly to operational and development readiness as it moves toward a pivotal maternal GBS vaccine trial [5].
What did the flu stem-vaccine study actually show?
The phase 1/2a report described broad humoral responses and acceptable tolerability in healthy adults, but it did not establish real-world efficacy yet [6].
Entities / Keywords
PCV13, 13-valent pneumococcal conjugate vaccine, pediatric IBD, inflammatory bowel disease, Crohn disease, ulcerative colitis
SK Bioscience, Songdo Global R&PD Center, GBP410, Sanofi, pneumococcal vaccine, mRNA platform, RSV monoclonal antibody
Moderna, mRNA-1010, mRESVIA, mRNA-1345, ESCMID 2026, influenza vaccine, RSV revaccination
IAVI, Marburg virus, rVSV∆G-MARV-GP, IAVI C104, Phase 1, outbreak response
Anixa Biosciences, breast cancer vaccine, lira-cel, ovarian cancer CAR-T
Evaxion, EVX-01, personalized cancer vaccine, advanced melanoma, pembrolizumab, Keytruda
Meiji Seika Pharma, Meiji Pharma Asia, Singapore, ASEAN, vaccines commercialization
References